Natalia Jura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/61985/publications.pdf

Version: 2024-02-01

257450 214800 7,837 46 24 47 citations h-index g-index papers 58 58 58 14884 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020, 583, 459-468.	27.8	3,542
2	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 2020, 370, .	12.6	508
3	Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment. Cell, 2009, 137, 1293-1307.	28.9	506
4	Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature, 2007, 450, 741-744.	27.8	311
5	Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21608-21613.	7.1	278
6	Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms. Molecular Cell, 2011, 42, 9-22.	9.7	265
7	A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochemical Journal, 2014, 457, 323-334.	3.7	241
8	Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature, 2022, 602, 487-495.	27.8	237
9	hSpry2 Is Targeted to the Ubiquitin-Dependent Proteasome Pathway by c-Cbl. Current Biology, 2003, 13, 308-314.	3.9	136
10	Structural Basis for the Non-catalytic Functions of Protein Kinases. Structure, 2016, 24, 7-24.	3.3	131
11	Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Communications Biology, 2021, 4, 475.	4.4	126
12	Receptor tyrosine kinase activation: From the ligand perspective. Current Opinion in Cell Biology, 2020, 63, 174-185.	5.4	109
13	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell, 2018, 34, 792-806.e5.	16.8	102
14	Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking. Science Advances, 2021, 7, .	10.3	100
15	Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Science Signaling, 2014, 7, ra114.	3.6	98
16	Prospects for pharmacological targeting of pseudokinases. Nature Reviews Drug Discovery, 2019, 18, 501-526.	46.4	83
17	Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor. Molecular and Cellular Biology, 2015, 35, 3083-3102.	2.3	74
18	EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2836-E2845.	7.1	63

#	Article	IF	CITATIONS
19	Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras. Cell Reports, 2018, 22, 2593-2600.	6.4	62
20	Feedback regulation of RTK signaling in development. Developmental Biology, 2019, 447, 71-89.	2.0	53
21	Structures of the HER2–HER3–NRG1β complex reveal a dynamic dimer interface. Nature, 2021, 600, 339-343.	27.8	48
22	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of <i>CASQ2 < /i>-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2020, 142, 932-947.</i>	1.6	44
23	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science, 2021, 374, eabf2911.	12.6	37
24	The pseudokinase <code><scp>TRIB</scp> 1</code> toggles an intramolecular switch to regulate <code><scp>COP</scp> 1</code> nuclear export. EMBO Journal, 2019, 38, .	7.8	31
25	Functional role of PGAM5 multimeric assemblies and their polymerization into filaments. Nature Communications, 2019, 10, 531.	12.8	30
26	Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene, 2019, 38, 1936-1950.	5.9	23
27	Activating HER3 mutations in breast cancer. Oncotarget, 2018, 9, 27773-27788.	1.8	23
28	The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. Journal of Biological Chemistry, 2019, 294, 13545-13559.	3.4	22
29	More than the sum of the parts: Toward fullâ€length receptor tyrosine kinase structures. IUBMB Life, 2019, 71, 706-720.	3.4	20
30	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. Journal of Clinical Investigation, 2021, 131, .	8.2	20
31	PEAK3/C19orf35 pseudokinase, a new NFK3 kinase family member, inhibits CrkII through dimerization. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15495-15504.	7.1	19
32	Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization. Nature Communications, 2021, 12, 4950.	12.8	15
33	The structure of a calsequestrin filament reveals mechanisms of familial arrhythmia. Nature Structural and Molecular Biology, 2020, 27, 1142-1151.	8.2	13
34	EGFR lung cancer mutants get specialized. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15169-15170.	7.1	12
35	Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Reports, 2022, 38, 110291.	6.4	7
36	Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Reports, 2022, 38, 110285.	6.4	7

#	Article	IF	CITATIONS
37	Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Structure, 2018, 26, 270-281.e4.	3.3	5
38	A survey of the kinome pharmacopeia reveals multiple scaffolds and targets for the development of novel anthelmintics. Scientific Reports, 2021, 11, 9161.	3.3	5
39	State of the structure address on MET receptor activation by HGF. Biochemical Society Transactions, 2021, 49, 645-661.	3.4	5
40	Piquing our interest: Insights into the role of PEAK3 in signaling and disease. Science Signaling, 2022, 15, eabm9396.	3.6	3
41	CNPY4 inhibits the Hedgehog pathway by modulating membrane sterol lipids. Nature Communications, 2022, 13, 2407.	12.8	3
42	Mutant HER2 needs mutant HER3 to be an effective oncogene. Cell Reports Medicine, 2021, 2, 100361.	6.5	2
43	An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1β heterocomplex and cryo-EM structure determination at low sample concentrations. Methods in Enzymology, 2022, 667, 633-662.	1.0	2
44	Switching on BTKâ€"One Domain at a Time. Structure, 2017, 25, 1469-1470.	3.3	1
45	Expression and purification of active human kinases using Pichia pastoris as a general-purpose host. Protein Expression and Purification, 2021, 179, 105780.	1.3	1
46	Efficient expression, purification, and visualization by cryo-EM of unliganded near full-length HER3. Methods in Enzymology, 2022, 667, 611-632.	1.0	0